Results 11 to 20 of about 16,960 (244)
Scientific Reports, 2022 To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto +10 more
doaj +2 more sources
Efficacy and Safety of Eplerenone for Treating Chronic Kidney Disease: A Meta-Analysis
International Journal of Hypertension, 2023 Background. In recent years, a large amount of clinical evidence and animal experiments have demonstrated the unique advantages of mineralocorticoid receptor antagonists (MRA) for treating chronic kidney disease (CKD). Aims.
Honglei Hu +5 more
doaj +2 more sources
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]
Diabetes Obes MetabAbstract The mineralocorticoid receptor (MR) has a multifaceted role in normal physiologic functions. However, research has uncovered the deleterious consequences of overactivation of the MR. It has been implicated in chronic kidney disease (CKD) via its strong association with glomerulosclerosis, interstitial fibrosis, proteinuria, and decline in ...
Mottl AK, Khunti K, Mathieu C.
europepmc +2 more sources
Journal of the American Society of Nephrology, 2022 Significance Statement In this randomized crossover clinical trial in patients with CKD with and without type 2 diabetes, we assessed the albuminuria-lowering effect of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin and ...
M. Provenzano +8 more
semanticscholar +1 more source
Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats [PDF]
Diabetes & Metabolism Journal, 2012 BackgroundAldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system.
Jae Hee Ahn +14 more
doaj +1 more source
Medical archives, 2023 Background: Heart failure remains one of the most prevalent clinical syndromes associated with significant morbidity and mortality. According to current guidelines, the prescription of a MRA is recommended to reduce the risk of HF hospitalization and ...
N. Naser +3 more
semanticscholar +1 more source
European Journal of Heart Failure, 2023 Eplerenone reduces the risk of cardiovascular death or first hospitalization for heart failure (HF) in patients with HF and a reduced ejection fraction (HFrEF), but it is still frequently underused in routine practice.
L. Monzo +9 more
semanticscholar +1 more source
Лечащий Врач, 2023 The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova +3 more
doaj +1 more source
Ophthalmology and Therapy, 2023 The aim of this work is to utilize swept-source optical coherence tomography angiography (SS-OCTA) to assess the long-term changes in the choroidal and choriocapillaris (CC) layers of the fellow unaffected eye of patients with unilateral resolved chronic
Pasquale Viggiano +8 more
semanticscholar +1 more source
Бюллетень сибирской медицины, 2021 Aim. To study the effect of eplerenone on the activity of free radical oxidation and renal function in rats with experimental diabetes mellitus induced by streptozotocin.Materials and methods. Experiments were carried out on 36 male Wistar rats. Diabetes
A. Yu. Zharikov +5 more
doaj +1 more source